Decision Letter for India Vaccine Support

Honorable Minister,

I am writing in relation to India's proposal to Gavi, The Vaccine Alliance, for New Vaccines Support (NVS) Inactivated Polio Vaccine (IPV) which was submitted to the Gavi Secretariat in September 2014. This letter is a revision of the Decision Letter sent to India on 5 June 2015 and replaces that letter.

This Decision Letter contains a revised total amount approved by Gavi for 2015 and 2016. The revision takes into consideration:

i) A funding of US$12 million from Global Polio Eradication Initiative (GPEI) partners (U.S. Centres for Disease Control and Prevention (CDC) and Rotary International) which was directly provided to UNICEF Supply Division, and therefore excluded from the Gavi funding;

ii) The Ministry's requests for additional 5-dose vials instead of 10-dose vials in view of the application of fractional IPV dose administration in a number of states.

India was allocated a combination of 5-dose and 10-dose vials because the global availability of 5-dose vials is insufficient to meet the full IPV requirements of India. The combined total number of doses funded by Gavi (14,884,210) and CDC/Rotary International (13,288,800) is 28,173,010. This has previously been confirmed and communicated to the Ministry by the UNICEF Supply Division in June 2016.

We note that the Gavi Board's decision to provide catalytic support for India's IPV programme was subject to three conditions, which are still currently valid:

i) The Ministry of Health and Family Welfare has satisfactorily addressed the IRC's comments in its letter dated March 5, 2015;

ii) The Global Polio Eradication Initiative (GPEI) has made available to Gavi additional financing for catalytic support for the first 12 months of India's programme;

iii) The Government of India has committed to continue to fund IPV when Gavi supports ends in a letter to GPEI dated January 30, 2015.
Please do not hesitate to contact my colleague Carol Szeto cszeto@gavi.org if you have any questions or concerns. We remain at your disposal for any further enquiry.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

Cc:
PS, The Minister of Health and Family Welfare
PS, The Minister of Finance
Secretary, Ministry of Health and Family Welfare
Additional Secretary, MD NHM, Ministry of Health and Family Welfare
Joint Secretary, Ministry of Health and Family Welfare
Deputy Commissioner (Immunization); MoHFW
Deputy Commissioner (UIP), MoHFW
WHO Country Representative
UNICEF Country Representative
WHO HQ
UNICEF Programme Division
UNICEF Supply Division
India Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: India


4. Date of the Partnership Framework Agreement: 16 June 2015

5. Programme title: NVS, IPV routine

6. Vaccine type: Inactivated Polio Vaccine (IPV)

7. Requested product presentation and formulation of vaccine:
   - Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID,
   - Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID


9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2015</th>
<th>2016</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV 5-dose(s) presentation (Grant number 1516-IND-25b-X)</td>
<td>US$2,311,100</td>
<td>US$1,931,240</td>
<td>US$4,242,340</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2015</th>
<th>2016</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV-10 dose(s) presentation (Grant number 1516-IND-25c-X)</td>
<td>US$3,911,377</td>
<td>US$8,377,827</td>
<td>US$12,289,204</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant (in US$): Not applicable

---

1 This is the entire duration of the Programme.
2 This is the revised total amount approved by Gavi for 2015 to 2016. The revision takes into account a funding of US$12M from CDC (7M doses) and Rotary International (5M doses) directly provided to UNICEF Supply Division and therefore not included as part of the Gavi-approved amount. The total number of doses funded by GPEI partners remain at a similar level as stated in the previous Decision Letter from 2015 (total of 28M doses).
11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)\(^3\)

IPV 5-dose(s) presentation (Grant number 1516-IND-25b-X)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>1,199,000</td>
<td>999,600</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$2,311,100</td>
<td>US$1,931,240</td>
</tr>
</tbody>
</table>

IPV 10-dose(s) presentation (Grant number 1516-IND-25c-X)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>4,539,500</td>
<td>8,146,110</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$3,911,377</td>
<td>US$8,377,827</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** Not applicable

13. **Self-procurement:** Country has elected to self-procure vaccines and injection safety devices in lieu of procuring through a Gavi agency. The applicable terms of the Partnership Framework Agreement and relevant Gavi guidelines and policies on self-procurement shall apply.

14. **Co-financing obligations:** Not applicable
   Gavi's usual co-financing requirements do not apply to IPV.

15. **Operational support for campaigns:** Not applicable

---

\(^3\) This is the revised total amount approved by Gavi for 2015 to 2016. The revision takes into account a funding of US$12M from CDC (7M doses) and Rotary International (5M doses) directly provided to UNICEF Supply Division and therefore not included as part of the Gavi-approved amount. The total number of doses funded by GPEI partners remain at a similar level as stated in the previous Decision Letter from 2015 (total of 28M doses).
### 16. Additional reporting requirements:

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

### 17. Financial clarifications:

Not applicable

### 18. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual number of doses available may differ from the amounts specified in this Decision Letter. In order to mitigate these circumstances, India is strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,

**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
22 August 2016